Building the World’s First Dedicated Drug Discovery Platform Centered on Protein Motion

Relay Therapeutics is committed to discovering and developing medicines that will make a transformative difference for patients by building the first dedicated drug discovery pipeline centered on protein motion. Bringing together the latest scientific advances in structural biology, biophysics, computation, chemistry and biology, Relay’s drug discovery engine illuminates the full mobility of a protein and the ways in which protein motion regulates function. By applying this approach as an integrated team focused on disease-causing targets, Relay aims to develop breakthrough medicines for patients in need. The company’s initial programs are focused on developing therapeutics in oncology. 

Year Invested: 2016
Location: Cambridge, Mass.

Recent News

December 14, 2017
Relay Therapeutics Secures $63 Million in Series B Financing

November 15, 2017
Relay Therapeutics Names Sarah O’Brien as Vice President of Human Resources

September 26, 2017
FierceBiotech Names Relay Therapeutics as one of its "Fierce 15" Biotech Companies of 2017

Read More News

Associated Team Members

Alexis Borisy